Pfizer and UCB Announce Formation of New Company Cyclofluidic to Accelerate Drug Discovery Process
- Details
- Category: Pfizer
Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB have announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time.
GSKâs Emerging Markets strategy advances with acquisition in Egypt
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has announced that it will acquire the Egyptian mature products business of Bristol Myers Squibb (BMS), for $210 (£125) million, in a move to accelerate sales growth and further extend its pharmaceutical portfolio in emerging markets.
Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications
- Details
- Category: Pfizer
Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID) pain medication Bextra, which Pfizer voluntarily withdrew from the U.S. market in 2005.
Abbott Reports Strong Sales and Earnings Growth in Third Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced financial results for the third quarter ended Sept. 30, 2008.
- Diluted earnings per share, excluding specified items, were $0.79, above Abbott's previously announced guidance range of $0.76 - $0.78, reflecting 17.9 percent growth.
GSK responds to NICE's second technology appraisal consultation document on the use of Tyverb
- Details
- Category: GlaxoSmithKline
The draft recommendations announced yesterday by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials.
European Journalists' Prize 2008 announced by Bayer HealthCare
- Details
- Category: Bayer
Scrupulously researched articles dealing with a topic from the worlds of medicine or health care - articles written in a critical, comprehensible, yet objective manner - have an excellent
chance of winning the 2008 European Journalists' Prize. The award, which is sponsored by Bayer HealthCare AG, Leverkusen/Germany, is endowed with EUR 7,500.
Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease
- Details
- Category: Novartis
An early proof-of-concept study shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in cardiac output, key hemodynamic measures used to monitor the progression of the disease.
More Pharma News ...
- Genzyme Recognized by Scientists as a Top Employer
- ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim
- Novo Nordisk and Innate Pharma swap product rights
- Bayer Reports Progress in Clinical Program for Riociguat
- Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
- Roche invests 215 million Swiss francs in diagnostics facility at Penzberg
- Shire Limited has changed its name to Shire plc